Ads
related to: abbvie pharmaceuticals- AbbVie News Center
See Our Achievements, Growth Story,
and More Today.
- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- AbbVie News Center
Search results
Quadruplet Regimens Have Become Standard for Multiple Myeloma
MedPage Today· 4 days agoWhile triplet regimens were once standard for newly diagnosed multiple myeloma, more recent studies...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoDiabetic Kidney Disease Market Size to Worth USD 5.32 Bn By 2031 PR Newswire BURLINGAME, Calif., May 28, 2024 BURLINGAME, Calif., May 28, 2024 /PRNewswire/ -- According to Coherent Market Insights, the global diabetic kidney disease market size
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 2 days agoEven so, the possible FDA approval of ivonescimab would serve as a testimony to Akeso’s in-house...
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 4 days agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
Morningstar· 6 days agoGilead Sciences GILD has relied on its HIV and hepatitis C portfolio to drive profit margins. Gilead...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoSlone Partners Places Kevin Eastwood as Chief Business Officer at Arpeggio Biosciences PR Newswire SOUTH RIDING, Va., May 29, 2024 Industry veteran brings more than 25 years of experience in senior leadership roles SOUTH RIDING, Va., May 29, 2024
Psychedelic Investing For Beginners: Seize The Golden Moment!
Benzinga· 6 days agoIn recent years, the landscape of medicine and mental health has been rapidly evolving, with...
Neurocrine Biosciences Announces CEO Succession Plan
KPVI· 6 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's ...
Ad
related to: abbvie pharmaceuticals